Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells
- PMID: 8787544
- DOI: 10.1016/0006-2952(96)00035-4
Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells
Abstract
The inhibition of thymidylate synthase (TS) as a drug development target has received much attention in recent years, and several compounds have reached clinical evaluation. During drug development, the effectiveness of target inhibition can be assessed by determination of the perturbations of deoxythymidine 5-triphosphate (TTP) and deoxyuridine 5'-monophosphate (dUMP) pools in drug-treated cells. Rapid, sensitive, and reproducible radioimmunoassays for TTP pools and immunoreactive dUMP pools have been developed to meet our requirement for the rapid assessment of TS inhibition by quinazoline antifolates. The assays can be carried out on 1-2 million cells, and require minimal sample preparation. The limit of detection for TTP is 1 pmole/10(6) cells and for immunoreactive dUMP ("dUMP"), 3.0 pmole/10(6) cells, both assays being performed on the same cell extract. TTP and "dUMP" pools have been measured in mouse L1210 leukaemia cells treated with the quinazoline antifolates ZD1694 (N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl )-N-methylamine]-2-thenoyl)-L-glutamic acid) and CB30900 (N-[N-[4-[N-[(3,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl ]-N-prop-2- ynylamino]-2-fluorobenzoyl]-L-gamma-glutamyl]-D-glutamic acid). Unlike ZD1694, CB30900 is a TS inhibitor that does not rely on polyglutamation for activity. In L1210 cells, both compounds caused a rapid inhibition of TTP pools in a dose- and time-related manner. Greater than 90% TS inhibition was achieved following a 4-hr exposure to each compound at equitoxic doses (up to 100 times the IC50 determine by a 48-hr growth inhibition assay). For both compounds, this was accompanied by a 5-10-fold increase in "dUMP" pools. For ZD1694, neither the TTP pool or "dUMP" levels were normalised when cells were resuspended in a drug-free medium for 4 hr and, at the higher doses studied, TS was still inhibited after a 16-hr period in the absence of drug. This is consistent with the formation and intracellular retention of potent polyglutamated forms of ZD1694. In contrast, TS activity as determined by repletion of the TTP pools and normalisation of "dUMP" levels were demonstrated for CB30900. However, at a high dose (50 microM, equivalent to 250 times the IC50), retention of TS inhibition was observed following 4 hr, but not 16 hr in the absence of drug. The radioimmunoassays described will prove useful to further define the extent and time-course of TS inhibition by novel antifolate compounds, and will also provide valuable in vitro and in vivo pharmacodynamic information on established antimetabolites when used alone or in combination with other drugs and modulators.
Similar articles
-
Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.Br J Cancer. 1995 May;71(5):914-24. doi: 10.1038/bjc.1995.178. Br J Cancer. 1995. PMID: 7537518 Free PMC article.
-
Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line.Biochem Pharmacol. 1995 Jul 31;50(3):391-8. doi: 10.1016/0006-2952(95)00135-m. Biochem Pharmacol. 1995. PMID: 7646540
-
Measurement of deoxyuridine triphosphate and thymidine triphosphate in the extracts of thymidylate synthase-inhibited cells using a modified DNA polymerase assay.Biochem Pharmacol. 1997 Sep 1;54(5):635-8. doi: 10.1016/s0006-2952(97)00259-1. Biochem Pharmacol. 1997. PMID: 9337081
-
Folate-based thymidylate synthase inhibitors as anticancer drugs.Ann Oncol. 1995 Nov;6(9):871-81. doi: 10.1093/oxfordjournals.annonc.a059353. Ann Oncol. 1995. PMID: 8624289 Review.
-
Thymidylate synthase inhibitors.Clin Cancer Res. 1996 Feb;2(2):227-43. Clin Cancer Res. 1996. PMID: 9816165 Review.
Cited by
-
Combination of gene/protein and metabolite multiomics to reveal biomarkers of nickel ion cytotoxicity and the underlying mechanism.Regen Biomater. 2024 Jun 29;11:rbae079. doi: 10.1093/rb/rbae079. eCollection 2024. Regen Biomater. 2024. PMID: 39022125 Free PMC article.
-
Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil.Cancer Manag Res. 2017 Oct 3;9:461-469. doi: 10.2147/CMAR.S113320. eCollection 2017. Cancer Manag Res. 2017. PMID: 29056855 Free PMC article. Review.
-
Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.Br J Cancer. 1998;78 Suppl 3(Suppl 3):27-34. doi: 10.1038/bjc.1998.751. Br J Cancer. 1998. PMID: 9717988 Free PMC article.
-
Synthesis of New 1, 3, 4-Oxadiazole-Incorporated 1, 2, 3-Triazole Moieties as Potential Anticancer Agents Targeting Thymidylate Synthase and Their Docking Studies.Pharmaceuticals (Basel). 2020 Nov 14;13(11):390. doi: 10.3390/ph13110390. Pharmaceuticals (Basel). 2020. PMID: 33202652 Free PMC article.
-
Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331.Br J Cancer. 2000 Sep;83(6):792-9. doi: 10.1054/bjoc.2000.1358. Br J Cancer. 2000. PMID: 10952785 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources